Lupin Q2 Hit By US Settlement, Japan Injectables Selloff
Goa, Somerset Plants Up For Re-inspection Jan-Mar
Executive Summary
Despite 10% revenue growth, Lupin ends up with a second-quarter loss from a one-time charge from settling a US lawsuit and the sale of its Japan injectables business. It's now counting on levothyroxine and secnidazole to carry it through the next few quarters, amid speculation that it might divest its Japanese subsidiary.
You may also be interested in...
Lupin Liquidating Japan JV With Yoshindo, Partners I’Rom For Denosumab Biosimilar
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.
Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
India 2019 – R&D Highs, Compliance Woes And Other Lows
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.